Kailera Therapeutics (NASDAQ:KLRA) Shares Climb 7.6% - Time to Buy?

Key Points

• Kailera Therapeutics shares rose 7.6% to $10.76 in mid-day trading, although volume was 65% below the average daily level.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $42.75, despite Weiss Ratings downgrading the stock to “sell (d-).”
• The clinical-stage obesity and metabolic-disease biotech reported a quarterly loss of $1.09 per share, missing estimates by $0.35, while several institutional investors—including Atlas Venture and Wellington Management—recently initiated sizable positions.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) were up 7.6% during mid-day trading on Friday. The company traded as high as $10.76 and last traded at $10.76. Approximately 293,082 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 844,615 shares. The stock had previously closed at $10.00.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Kailera Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $42.75.

Kailera Therapeutics Stock Performance

The firm has a market cap of $1.47 billion and a price-to-earnings ratio of -0.00. The firm has a 50 day moving average price of $15.14.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Kailera Therapeutics in the second quarter valued at approximately $113,923,000. Wellington Management Group LLP acquired a new stake in Kailera Therapeutics in the 2nd quarter worth $64,308,000. Frazier Life Sciences Management L.P. bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth about $24,233,000. State Street Corp acquired a new position in shares of Kailera Therapeutics during the second quarter valued at about $19,126,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Kailera Therapeutics in the second quarter valued at about $993,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company's research is centered on therapies designed to address weight management and related health conditions.

Kailera's pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.